Bioconscientia LLC

Longhorn Life Sciences Inc. is a MedTech venture based in Austin, TX, founded by a diverse team of scientists, clinicians, and entrepreneurs from UT Austin and MD Anderson. Their mission centers on developing innovative medical technology solutions aimed at enhancing patient outcomes, particularly in the management of post-operative wound care at home. Since its inception in July 2021, Longhorn Life Sciences has engaged with strategic partners, including established wound care device manufacturers and organizations like NASA and the Department of Defense. The company has actively participated in various pitch competitions and customer discovery interviews, validating the clinical need for their flagship product, the Infection Detective. Generated from the website

Nanohmics, Inc is an aggressive company founded in July 2002 by entrepreneur-minded scientists and engineers. Nanohmics specializes in technology development for commercial instrumentation and innovative materials/instrumentation engineering solutions developed through contract research and the Small Business Innovative Research ( SBIR ) program. The technical staff includes backgrounds in materials science, materials chemistry, optical physics, electro-optics engineering, electrical engineering, mechanical engineering and industrial design. Since Nanohmics initial Phase I SBIR selections from NASA in early 2003, Nanohmics has been awarded SBIR contracts from the National Institute of Health, National Science Foundation, Department of Energy, Office of the Secretary of Defense, Homeland Security, Missile Defense Agency, National Oceanic and Atmospheric Administration, US Army, US Air Force, US Navy, and Marine Corp. In addition, Nanohmics has seen tremendous growth in its commercial instrumentation engineering and product development programs that include contracts with early stage technology startup companies to Fortune 500 companies in the aerospace and biotechnology areas. Nanohmics gross revenues have grown during each year of operation with about 60% from the government sponsored SBIR program and the rest through commercial contracts and sales. Revenue growth is a result of the expansion of Nanohmics contract engineering business unit and increased number of R&D contracts. Nanohmics has recently moved to a 7000 square foot office/laboratory complex and invested internal funds to build-out R&D facilities that include engineering and development space, optical laboratory, vacuum deposition and materials fabrication facilities, a wet laboratory for materials/chemistry processing and ample office space for hardware and software design. In addition, Nanohmics has built out low-volume manufacturing space for production assembly of engineered systems. Nanohmics mission is to provide high quality engineering solutions and low volume production of high value products through close cooperative development agreements with key strategic partners. A portion of this mission includes technology innovation from strategic SBIR funded programs. Present programs include high precision optical scattering instrumentation and analysis and other optoelectronic applications in biotechnology as well as custom material and nanostructured material components that advance existing devices. Nanohmics is committed to commercializing the results of its research programs either by spinning out the technology developed, licensing the technology to development partner companies or developing the technology internally to a level that will enable retention of a sizable equity position for prospective venture-backed opportunities. Nanohmics' management has extensive knowledge in the identification of business opportunities that are attractive for continued investment following successful technical development. In particular, they have a proven track record of developing SBIR-initiated products as well as securing and directing venture capital backing for product commercialization. Nanohmics has low volume manufacturing capabilities and has manufactured a number of devices for commercial sale in low volume ( 10-100 devices ) production runs. Nanohmics' personnel understand the process necessary to select, and strategically position opportunities developed through contract research and the SBIR programs. Nanohmics' intension is to keep its core focus on technology incubation while pursuing other vehicles for commercialization of mature or ready-for-market technology. Commercialization mechanisms include selling or licensing the technology, setting up subsidiary corporations in order to attract follow-on and/or matching capital from established venture capital firms, angel investors, and investments from larger corporations interested in the technology. Nanohm

Neurox1 Inc, based in Austin, TX, is dedicated to leveraging innovative technology to provide exceptional services aimed at enhancing user experience. The company places a strong emphasis on data privacy, ensuring that all personal information collected is handled with care and in compliance with relevant regulations. With a commitment to transparency, Neurox1 Inc shares its privacy practices openly, informing users about the types of personal data collected and how it is utilized. The organization continually revises its policies to adapt to changing standards, maintaining a focus on user consent and data protection. Generated from the website